Document Detail


Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.
MedLine Citation:
PMID:  19179465     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In paroxysmal nocturnal hemoglobinuria (PNH) hemolytic anemia is due mainly to deficiency of the complement regulator CD59 on the surface of red blood cells (RBCs). Eculizumab, an antibody that targets complement fraction 5 (C5), has proven highly effective in abolishing complement-mediated intravascular hemolysis in PNH; however, the hematologic benefit varies considerably among patients. In the aim to understand the basis for this variable response, we have investigated by flow cytometry the binding of complement fraction 3 (C3) on RBCs from PNH patients before and during eculizumab treatment. There was no evidence of C3 on RBCs of untreated PNH patients; by contrast, in all patients on eculizumab (n = 41) a substantial fraction of RBCs had C3 bound on their surface, and this was entirely restricted to RBCs with the PNH phenotype (CD59(-)). The proportion of C3(+) RBCs correlated significantly with the reticulocyte count and with the hematologic response to eculizumab. In 3 patients in whom (51)Cr labeling of RBCs was carried out while on eculizumab, we have demonstrated reduced RBC half-life in vivo, with excess (51)Cr uptake in spleen and in liver. Binding of C3 by PNH RBCs may constitute an additional disease mechanism in PNH, strongly enhanced by eculizumab treatment and producing a variable degree of extravascular hemolysis.
Authors:
Antonio M Risitano; Rosario Notaro; Ludovica Marando; Bianca Serio; Danilo Ranaldi; Elisa Seneca; Patrizia Ricci; Fiorella Alfinito; Andrea Camera; Giacomo Gianfaldoni; Angela Amendola; Carla Boschetti; Eros Di Bona; Giorgio Fratellanza; Filippo Barbano; Francesco Rodeghiero; Alberto Zanella; Anna Paola Iori; Carmine Selleri; Lucio Luzzatto; Bruno Rotoli
Related Documents :
595085 - A study of the presence of circulating immune complexes in schistosomiasis.
2530015 - Differences in the metabolism of c4 isotypes in patients with complement activation.
21347595 - The absence of coronary artery calcification does not rule out the presence of signific...
18783065 - Serum complement (c3, c4) levels in patients with acute myocardial infarction and angin...
16601385 - Is free/total psa predictive of pathological stage and gleason score in patients with p...
23049545 - The role of helicobacter pylori and nsaids in the pathogenesis of uncomplicated duodena...
Publication Detail:
Type:  Journal Article     Date:  2009-01-29
Journal Detail:
Title:  Blood     Volume:  113     ISSN:  1528-0020     ISO Abbreviation:  Blood     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-04-24     Completed Date:  2009-05-08     Revised Date:  2013-11-25    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4094-100     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / immunology*,  therapeutic use*
Antibodies, Monoclonal, Humanized
Cell Survival
Complement C3 / metabolism*
Erythrocytes / metabolism*,  pathology
Female
Flow Cytometry
Hemoglobinuria, Paroxysmal / immunology,  metabolism*,  therapy*
Humans
Immunotherapy*
Male
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Complement C3; A3ULP0F556/eculizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a ...
Next Document:  Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma ...